全球生物标记市场规模、份额、趋势和成长分析报告（2026-2034年）

预计生物标记市场将从 2025 年的 2,092.1 亿美元成长到 2034 年的 6,570.7 亿美元，2026 年至 2034 年的复合年增长率为 13.56%。

受精准医疗和疾病早期检测需求不断增长的推动，全球生物标记市场正经历强劲增长。生物标记广泛应用于诊断、药物研发和临床研究，用于评估疾病进展和治疗效果。癌症和心血管疾病等慢性病盛行率的上升进一步推动了市场扩张。

基因组学、蛋白质组学和分子诊断技术的进步是关键的成长要素。製药公司越来越多地在临床试验中使用生物标记物，以提高药物的疗效和安全性。此外，研发投入的增加以及生技公司与学术机构之间合作的加强，正在加速创新。

展望未来，人工智慧（AI）和巨量资料分析的融合预计将对市场产生积极影响。个人化医疗的进步将进一步提升对生物标记检测的需求。开发中国家医疗基础设施的扩建也将创造新的机会。随着诊断技术的不断发展，生物标记市场有望实现长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球生物标记市场：按类型划分

• 市场分析、洞察与预测
• 安全生物标记
• 疗效生物标记
• 预测性生物标记
• 替代生物标记
• 药物动力学生物标记物
• 预后生物标记
• 检验生物标记

第五章 全球生物标记市场：依产品划分

• 市场分析、洞察与预测
• 消耗品
• 服务
• 软体

第六章 全球生物标记市场：依应用划分

• 市场分析、洞察与预测
• 诊断
• 药物发现与开发
• 个人化医疗
• 疾病风险评估
• 其他的

第七章 全球生物标记市场：依疾病分类

• 市场分析、洞察与预测
• 癌症
• 心血管疾病
• 神经系统疾病
• 免疫疾病
• 其他的

第八章 全球生物标记市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Epigenomics AG
  • GE HealthCare Technologies Inc
  • Johnson & Johnson Services Inc
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories Inc
  • Siemens Healthineers AG
  • QIAGEN NV
  • Merck KGaA
  • PerkinElmer Inc
  • Agilent Technologies Inc
  • Eurofins Scientific SE

The Biomarkers Market size is expected to reach USD 657.07 Billion in 2034 from USD 209.21 Billion (2025) growing at a CAGR of 13.56% during 2026-2034.

The Global Biomarkers Market is experiencing strong growth due to rising demand for precision medicine and early disease detection. Biomarkers are widely used in diagnostics, drug development, and clinical research to assess disease progression and treatment response. Increasing prevalence of chronic diseases such as cancer and cardiovascular disorders is fueling market expansion.

Key growth drivers include advancements in genomics, proteomics, and molecular diagnostics technologies. Pharmaceutical companies are increasingly utilizing biomarkers in clinical trials to improve drug efficacy and safety. Additionally, growing investments in research and development and collaborations between biotech firms and academic institutions are accelerating innovation.

Looking ahead, the market is expected to benefit from integration with artificial intelligence and big data analytics. Personalized medicine initiatives will further increase demand for biomarker-based testing. Expanding healthcare infrastructure in developing economies will create new opportunities. As diagnostic technologies continue to evolve, the biomarkers market is poised for long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamic Biomarkers
• Prognostics Biomarkers
• Validation Biomarkers

By Product

• Consumable
• Services
• Software

By Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

By Disease

• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Abbott Laboratories, Epigenomics AG, GE HealthCare Technologies Inc, Johnson Johnson Services Inc, Thermo Fisher Scientific Inc, BioRad Laboratories Inc, Siemens Healthineers AG, QIAGEN NV, Merck KGaA, PerkinElmer Inc, Agilent Technologies Inc, Eurofins Scientific SE
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Safety Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Efficacy Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Surrogate Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Pharmacodynamic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Prognostics Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Validation Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOMARKERS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Consumable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Disease Risk Assessment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOMARKERS MARKET: BY DISEASE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Disease
• 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Immunological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Product
  • 8.2.3 By Application
  • 8.2.4 By Disease
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Product
  • 8.3.3 By Application
  • 8.3.4 By Disease
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Product
  • 8.4.3 By Application
  • 8.4.4 By Disease
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Product
  • 8.5.3 By Application
  • 8.5.4 By Disease
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Product
  • 8.6.3 By Application
  • 8.6.4 By Disease
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOMARKERS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 F. Hoffmann-La Roche Ltd
  • 10.2.2 Abbott Laboratories
  • 10.2.3 Epigenomics AG
  • 10.2.4 GE HealthCare Technologies Inc
  • 10.2.5 Johnson & Johnson Services Inc
  • 10.2.6 Thermo Fisher Scientific Inc
  • 10.2.7 Bio-Rad Laboratories Inc
  • 10.2.8 Siemens Healthineers AG
  • 10.2.9 QIAGEN N.V
  • 10.2.10 Merck KGaA
  • 10.2.11 PerkinElmer Inc
  • 10.2.12 Agilent Technologies Inc
  • 10.2.13 Eurofins Scientific SE